Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 12;3(6):e1232186.
doi: 10.1080/23723556.2016.1232186. eCollection 2016.

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers

Anthony Ferrari  1 , Anne-Sophie Sertier  1 , Anne Vincent-Salomon  2 , Xavier Pivot  3 , Iris Pauporté  4 , Pierre Saintigny  5 , Daniel Birnbaum  6 , Alain Viari  7
Affiliations

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers

Anthony Ferrari et al. Mol Cell Oncol. .

Abstract

Analysis of gene expression and whole-genome features of 64 human epidermal growth factor 2 (HER2)-positive breast tumors supports the idea that their intrinsic heterogeneity actually reflects their cell of origin, suggesting that HER2 amplification is an embedded event in the natural history of these tumors. Possible mechanisms for this event involve breakage-fusion-bridge and chromothripsis.

Keywords: Breakage-Fusion-Bridge; Breast cancer; ERBB2 amplification; cancer genomics; mammary epithelial hierarchy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Mammary epithelial hierarchy and genomic features of epidermal growth factor 2-positive breast cancer. From left to right: developmental stage of normal epithelial mammary cells; amplification events: erb-b2 receptor tyrosine kinase 2 (ERBB2), cyclin D1 (CCND1), and zinc finger protein 703 (ZNF703); RNA expression groups (A, B, C, and D); PAM50 intrinsic subtypes (luminal A, luminal B, HER2-enriched, and basal); genomic features: fraction of genome altered (FGA); mutations in tumor protein p53 (TP53) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA).
See this image and copyright information in PMC

References

    1. Slamon D, Eiermann W, Robert N, Pienkowski T, Martín M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al.. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273-83; PMID:21991949; http://dx.doi.org/10.1056/NEJMoa0910383 - DOI - PMC - PubMed
    1. Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst 2014; 106:dju152; PMID:25139534; http://dx.doi.org/10.1093/jnci/dju152 - DOI - PMC - PubMed
    1. Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström P-O, Johannsson OT, et al.. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 2010; 12:R25; PMID:20459607; http://dx.doi.org/10.1186/bcr2568 - DOI - PMC - PubMed
    1. Bianchini G, Pusztai L, Pienkowski T, Im Y-H, Bianchi GV, Tseng L-M, Liu M-C, Lluch A, Galeota E, Magazzù D, et al.. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann Oncol 2015; 26:2429-36; PMID:26387142; http://dx.doi.org/10.1093/annonc/mdv395 - DOI - PubMed
    1. Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, et al.. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol 2015; 34:542-9; PMID:26527775; http://dx.doi.org/10.1200/JCO.2015.62.1268 - DOI - PMC - PubMed

LinkOut - more resources